Sign in

CIK 0002002988 · <br>Emerging growth company

Retension Pharmaceuticals, Inc.

Sign in to watch
Ticker
RTSN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
other
EIN
932592788
Phone
(703) 624-2024
Business address
C/O REDUX THERAPEUTICS, LLC, 902 TURKEY RUN ROAD, MCLEAN, VA, 22101
Open-market buys, last 90 days
$369,600
in 2 filings
Open-market sales, last 90 days
$0
in 0 filings

Net +$369,600. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Keller Eric L. +$250K CHIEF EXECUTIVE OFFICER 1 filing
  2. BERGER FRANKLIN M +$120K Director 1 filing
Date Insider Transaction Shares Price Value Owned after
2026-11-02 Wong Robert VP, Chief Accounting Officer Grant or award · Stock Option (right to buy) +25,000 25,000
2026-10-22 Keller Eric L. CHIEF EXECUTIVE OFFICER Grant or award · Stock Option (right to buy) +40,884 40,884
2026-10-13 Keller Eric L. CHIEF EXECUTIVE OFFICER Purchase +20,800 $12.00 $250K 423,377
2026-10-13 Keller Eric L. CHIEF EXECUTIVE OFFICER Conversion +9,662 433,039
2026-10-13 Keller Eric L. CHIEF EXECUTIVE OFFICER Conversion +31,368 464,407
2026-10-13 Keller Eric L. CHIEF EXECUTIVE OFFICER Grant or award · Stock Option (right to buy) +255,174 255,174
2026-10-13 Keller Eric L. CHIEF EXECUTIVE OFFICER Conversion · Series A Convertible Preferred Stock −9,662 0
2026-10-13 Keller Eric L. CHIEF EXECUTIVE OFFICER Conversion · Series B Convertible Preferred Stock −31,368 0
2026-10-13 Sweetnam Paul CHIEF SCIENTIFIC OFFICER Conversion +4,026 406,603
2026-10-13 Sweetnam Paul CHIEF SCIENTIFIC OFFICER Conversion +2,640 2,640
2026-10-13 Sweetnam Paul CHIEF SCIENTIFIC OFFICER Conversion · Series A Convertible Preferred Stock −4,026 0
2026-10-13 Sweetnam Paul CHIEF SCIENTIFIC OFFICER Conversion · Series B Convertible Preferred Stock −2,640 0
2026-10-13 Olds Donald Director Conversion +5,637 5,637
2026-10-13 Olds Donald Director Conversion · Series A Convertible Preferred Stock −5,637 0
2026-10-13 Cheruvu Pavan Director Grant or award · Stock Option (right to buy) +5,636 5,636
2026-10-13 Bisson Sabine CHIEF OPERATING OFFICER Conversion +1,611 1,611
2026-10-13 Bisson Sabine CHIEF OPERATING OFFICER Conversion +2,504 4,115
2026-10-13 Bisson Sabine CHIEF OPERATING OFFICER Conversion · Series A Convertible Preferred Stock −1,611 0
2026-10-13 Bisson Sabine CHIEF OPERATING OFFICER Conversion · Series B Convertible Preferred Stock −2,504 0
2026-10-13 BERGER FRANKLIN M Director Conversion +12,517 12,517

Page 1 of 2 · 29 trades